Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Inclusion Criteria: * CD30 detectable B lineage relapsed refractory NHL including the following histologies: * Aggressive lymphomas: diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, grey zone lymphomas, high grade B cell lymphomas, and transformed indolent lymphomas * Indolent lymphoma: follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma; indolent lymphoma patients eligible for this trial should have high tumor burden and high risk disease, as defined by: * The Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria * Intermediate or high risk by Follicular Lymphoma International Prognostic Index (FLIPI) score or elevated lactose dehydrogenase (LDH)/ beta-2 microglobulin (B2M) * Subjects between 18 and 75 years old. Subjects older than 75 years old to be discussed with PI prior to subject consent; consensus between PI and treating physician is required. * Karnofsky performance status (KPS) \>= 70%, Eastern Cooperative Oncology Group (ECOG) =\< 2 * At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma * Patients must have received at least one but no more than 4 prior lines of systemic therapy * American Heart Association (AHA) class 1 without significant limitation of physical activity * Ejection fraction (EF) of at least \>= 40% by multigated acquisition (MUGA) or echocardiography (ECHO) * Total bilirubin =\< 1.5 mg/dl * Alanine aminotransferase (ALT), aspartate aminotransf…